14. E. Vilella #, G. Bengtsson-Olivecrona*, T. Stigbrand*, and P. E. H. Jensen*, Biochemistry and Biophysics, University of Umeå, Umeå, Sweden.

Transcription

1 February 204 PUBLICATIONS. Poul Erik Hyldgaard Jensen. P. E. H. Jensen and L. Sottrup-Jensen, Dept. of Molecular Biology and Plant Physiology, Aarhus University, Aarhus, Denmark. Primary Structure of Human 2-Macroglobulin. Complete disulfide bridge assignment and localization of two interchain bridges in the dimeric proteinase binding unit. J. Biol. Chem., Vol. 26, No.34, pp , P. A. Roche, P. E. H. Jensen, and S. V. Pizzo, Dept. of Pathology, Duke University, Durham, NC, USA. Intersubunit Cross-linking by cis-dichlorodiammineplatinum (II) Stabilizes an 2- Macroglobulin "Nascent" State: Evidence That Thiol Ester Bond Cleavage Correlates with Receptor Recognition Site Exposure. Biochemistry, Vol. 27, No.2, pp , P. E. H. Jensen and S. V. Pizzo, Dept. of Pathology, Duke University, Durham, NC, USA. Comparison of 2-Macroglobulin Receptors From Human, Baboon, Rat, and Mouse Liver. Biochem. Archives, Vol. 5, pp. 7-76, P. E. H. Jensen*, G. Birkenmeier#, and T. Stigbrand*, *Dept. of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden, and # Dept. of Physiological Chemistry, Leipzig, Germany. Zinc Chelates Bind Human Hemopexin. Acta Chem. Scand., 45, pp , P. E. H. Jensen and T. Stigbrand, Dept. of Medical Biochemistry, University of Umeå. Sweden Immunochemical Studies of 2-Macroglobulin ( 2M) and Pregnancy Zone Protein (PZP) Derivatives. Biol. Chem. Hoppe-Seyler, Vol. 372, no. 3, pp.39, P. E. H. Jensen and T. Stigbrand, Dept. of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden. Differences in the Proteinase Inhibition Mechanism of Human 2-Macroglobulin and Pregnancy Zone Protein. Eur. J. Biochem. 20, pp , P. E. H. Jensen*, E.-M. Hägglöf+, L. Arbelaez*, T. Stigbrand*, and V. P. Shanbhag+, *Department of Medical Biochemistry and Biophysics, + Dept. of Biochemistry, Umeå University, Umeå, Sweden. Comparison of Conformational Changes of Pregnancy Zone Protein and Human 2- Macroglobulin. A study using hydrophobic affinity partitioning. Biochim. Biophys. Acta 64, pp , 993

2 2 8. L. F. Arbelaez*, P. E. H. Jensen*, V. P. Shanbhag+, and T. Stigbrand*, *Dept. of Medical Biochemistry and Biophysics, + Dept. of Biochemistry, Umeå University, Umeå, Sweden. Probing different conformational states of pregnancy zone protein: fluorescence studies with 4.4.'bis [8-anilino--naphtalenesulphonate] (bis-ans). Eur. J. Biochem. 28, pp , P. E. H. Jensen Mechanisms of Proteinase Inhibition by Human 2-Macroglobulin and Pregnancy Zone Protein. Medical Dissertation, 993, New Series No 389, ISSN From the Department of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden. 0. P. E. H. Jensen*, T. Stigbrand*, and V. P. Shanbhag+, *Dept. of Medical Biochemistry and Biophysics, + Dept. of Biochemistry, University of Umeå, Umeå, Sweden. Use of hydrophobic affinity partitioning as a method to study various conformational states of the human -macroglobulins. J. Chromatography, 668, No., pp. 0-06, 994. E. Vilella #, G. Bengtsson-Olivecrona*, T. Stigbrand*, and P. E. H. Jensen*, # Center of Biomedical Research, Hospital de Sant Joan, Reus, Spain, *Depart. of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden. Binding of lipoprotein lipase to 2-macroglobulin. Biochemical J. 300, pp , P. E. H. Jensen*, V. P. Shanbhag+, and T. Stigbrand*, *Department of Medical Biochemistry and Biophysics, +Department of Biochemistry, Umeå University, Sweden Methanethiolation of the liberated Cysteine Residues of Human 2-Macroglobulin treated with Methylamine Generates a Derivative with similar functional Characteristics As Native 2-Macroglobulin. Eur. J. Biochem. 227, pp , P. E. H. Jensen*, V. P. Shanbhag+, and T. Stigbrand*, *Dept. of Medical Biochemistry and Biophysics, + Dept. of Biochemistry, Umeå University, Umeå, Sweden Disulfide Bond Formation by Methanethiolation of the Thiol Ester Sulfhydryl Group of 2M. "Biology of 2-Macroglobulin, its receptor and related proteins" in Annals of The New York Academy of Sciences, vol.737, pp , E. Vilella #, G. Bengtsson-Olivecrona*, T. Stigbrand*, and P. E. H. Jensen*, # Center of Biomedical Research, Hospital de Sant Joan, Reus, Spain, *Depart. of Medical Biochemistry and Biophysics, University of Umeå, Umeå, Sweden. Binding of lipoprotein lipase to 2-macroglobulin. "Biology of 2-Macroglobulin, its receptor and related proteins" in

3 3 Annals of The New York Academy of Sciences, vol.737, pp , A. Mottaqui-Tabar+, P. E. H. Jensen*, T. Stigbrand*, B.-H. Jonsson+, and V. P. Shanbhag+, *Dept. of Medical Biochemistry and Biophysics, + Dept. of Biochemistry, Umeå University, Umeå, Sweden Cloning and Expression of the 5 kda C-terminal peptide from the human 2- Macroglobulin as a fusion-protein product in a Procaryotic Cell Line. "Biology of 2-Macroglobulin, its receptor and related proteins" in Annals of The New York Academy of Sciences, vol.737, pp , L. F. Arbelaez, P. E. H. Jensen, and Torgny Stigbrand, Dept. of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden Proteinases from the Fibrinolytic System: Analyses of Binding to Pregnancy Zone Protein, a Pregnancy-associated Plasma Proteinase Inhibitor. Fibrinolysis 9, pp. 4-47, P. E. H. Jensen and T. Stigbrand, Dept. of Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden. Malfunctioning 2-Macroglobulin in patients with Multiple Sclerosis. Journal of Neuroimmunologi, Supplement, 39, P. E. H. Jensen*, L. Arbelaez*, V. P. Shanbhag+, and T. Stigbrand*, *Dept. of Immunology, Umeå University, Umeå, + Dept. of Biochemistry, Umeå University, Umeå, Sweden. Preparation and Characterization of a C-terminal Fragment of Pregnancy Zone Protein corresponding to the Receptor-binding Peptide from Human 2-Macroglobulin. Biochem. Biophys. Acta 293, pp , V. P. Shanbhag+, T. Stigbrand*, and P. E. H. Jensen*, Dept. of Biochemistry, +Dept. of Immunology, *Dept. of Biochemistry, Umeå University, Umeå, Sweden The Conformational State of Human 2 -Macroglobulin Influences Its Dissociation into Half-Molecules by Sodium Thiocyanate. Arch. Biochem. Biophys. 333, no., pp. 35-4, V. P. Shanbhag+, T. Stigbrand*, and P. E. H. Jensen*, +Dept. of Immunology, *Dept. of Biochemistry, Umeå University, Umeå, Sweden. The Contact Zones in Human 2 -Macroglobulin. Functional domains important for the Regulation of the Trapping Mechanism. Eur. J. Biochem. 244, no. 3, pp , M. Gunnarsson and P. E. H. Jensen, Alpha-2-macroglobulin is a binding protein for soluble myelin basic protein in human serum. Multiple Sclerosis, 3, no. 5, P36, pp. 37, M. Gunnarsson and P. E. H. Jensen,

4 4 Binding of Soluble Myelin Basic Protein to Various Conformational Forms of alpha2- Macroglobulin. Arch. Biochem. Biophys. 359, no.2, pp , M. Gunnarsson and P. E. H. Jensen, Soluble myelin basic protein is protected against proteolytic degradation by binding to 2 - Macroglobulin. Tumor Biology 9, S2, P-30, pp. 77, P. E. H. Jensen, M. Gunnarsson, M. Boström, and T. Stigbrand, Biology of 2 -Macroglobulin and Pregnancy Zone Protein. Tumor Biology 9, S2, 0-39, pp. 32, M. Gunnarsson and P. E. H. Jensen, Soluble myelin basic protein is protected against proteolytic degradation by binding to 2 - Macroglobulin. Multiple Sclerosis 4, no. 4, P003, pp. 284, N. Saidi, M. Samel*, J. Siigur*, and P. E. H. Jensen,, and *National Institute of Chemical Physics and Biophysics, Tallin, Estonia, Neuroimmunology Laboratory, Rigshospitalet, Copenhagen Denmark. Lebetase, an )-fibrin(ogen)olytic metalloproteinase of Vipera lebetina snake venom, is inhibited by human -macroglobulins. Biochim. Biophys. Acta 434, pp , M. Gunnarsson, T. Stigbrand, and P. E. H. Jensen*, Decreased stability of 2 -Macroglobulin purified from patients with Multiple Sclerosis. Acta Neurol. Scand. 0(4), pp , M. Gunnarsson, T. Stigbrand, and P. E. H. Jensen*, Aberrant forms of 2 -Macroglobulin purified from patients with Multiple Sclerosis. Clin Chim Acta. 295(-2), pp , M. Gunnarsson, T. Stigbrand, and P. E. H. Jensen* Conformational variants of human 2 -Macroglobulin are reflected in a C-terminal switch region Eur. J. Biochem. 267 (3), pp , 2000

5 5 30. M. Gunnarsson, T. Stigbrand, and P. E. H. Jensen*, Dept. of Immunology, Umeå University, Umeå; *Neuroimmunology Laboratory,. Immunochemical aberrations of alpha2-macroglobulin purified from a patient with multiple sclerosis. Acta Neurol. Scand. 02(6), pp , P. E. H. Jensen*, T. Stigbrand, and M. Gunnarsson Dept. of Immunology, Umeå University, Umeå; *Neuroimmunology Laboratory,. Abnormal 2 -macroglobulin purified from patients with multiple sclerosis. Revue Neurologique supplément 3, pp 3S84, P. E. H. Jensen *, M. Gunnarsson, and T. Stigbrand, Neuroimmunology Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; * Conformational state and receptor recognition of the C-terminal domain of human 2- macroglobulin after dissociation into half-molecules. Clin Chim Acta 30, pp , M. Gunnarsson, T. Stigbrand, and P. E. H. Jensen*, Decreased stability 2 -Macroglobulin purified from patients with Multiple Sclerosis. Year Book of Pathology and Clinical Pathology, Mosby-Year Book, Inc M. Gunnarsson, L. Frängsmyr, T. Stigbrand, and P. E. H. Jensen*, Stimulation of peripheral blood mononuclear cells with lipopolysaccharide induces expression of the plasma protein 2 -macroglobulin. Protein Expression and Purification, 27(2):238-43, M. Gunnarsson, P. Sundström, T. Stigbrand, and P. E. H. Jensen*, Native and transformed 2 -macroglobulin in plasma from patients with multiple sclerosis. Acta Neurol. Scand. 08, pp. 6-2, P. E. H. Jensen, S. Humle Jørgensen, P. Datta, and P. Soelberg Sørensen, The Neuroimmunology Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark Significantly increased fractions of transformed to total 2 -macroglobulin concentrations in plasma from patients with multiple sclerosis. Biochimica et Biophysica Acta, Molecular Basis of Disease, 690(3), pp , 2004.

6 6 37. SH Jørgensen, PEH Jensen, H Laursen, and PS Sørensen, The Neuroimmunology Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurological Research, 27 (6) pp.59-7, SH Jørgensen, N Storm, PE Jensen, H Laursen, and PS Sørensen, Danish MS Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, Laboratory of Neuropathology,, IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Experimental Brain Research, 78(4) pp , M Ravnborg,,2 K Bendtzen, 2 O Christensen, PEH Jensen, D Hesse, 3 MG Tovey, and PS Sørensen, Danish MS Research Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, Institute for Inflammation Research,, 2 Biomonitor, Symbion Park, Copenhagen, Denmark, 3 Laboratory of Viral Oncology, CNRS FRE2937, Institute Andre Lwoff, 9480 Villejuif, France. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with MS. Multiple Sclerosis, 5: , AB Oturai,,2 N Koch-Henriksen, 3 T Petersen, PEH Jensen, F Sellebjerg, and PS Sørensen, University Hospital, Rigshospitalet, Copenhagen, Denmark, Danish Multiple Sclerosis Treatment Registry, Rigshospitalet, Copenhagen, 2 University Hospital in Aalborg, Aalborg, and 3 Department of Neurology, Århus University Hospital, Århus, Denmark. Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. European Journal of Neurology, 6: , F Sellebjerg, M Krakauer, D Hesse, LP Ryder, I Alsing, PEH Jensen, 2 N Koch- Henriksen, A Svejgaard, and P Soelberg Sørensen. University Hospital, Rigshospitalet, Copenhagen, Denmark, Department of Clinical Immunology, Tissue Typing Laboratoy, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, and 2 University Hospital in Aalborg, Aalborg. Identification of new sensitive biomarkers for the in vivo response to interferon- treatment in multiple sclerosis using DNA-array evaluation. European Journal of Neurology, 6(2): , Per Soelberg Sørensen, Nils Koch-Henriksen 2, Poul Erik Hyldgaard Jensen. University Hospital, Rigshospitalet, Copenhagen, Denmark, and 2 University Hospital in Aalborg, Aalborg.

7 7 Neutralizing antibodies against interferon-beta do not predispose antibodies against natalizumab. Neurology, 76: , Per Soelberg Sorensen, Poul Erik Hyldgaard Jensen, Aiden Haghikia 2, Malin Lundkvist 3, Christian Vedeler 4, Finn Sellebjerg, Nils Koch-Henriksen 5, anna Fogdell- Hahn 3, Kjell-Morten Myhr 4, Jan Hillert 3, Ralf Gold 2. University Hospital, Rigshospitalet, Copenhagen, Denmark, 2 Department of Clinical Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany; 3 Department of Clinical Neuroscience, Division of Neurology, Karolinska Institutet, Huddinge, Sweden; 4 Department of Neurology, Haukeland University Hospital, University of Bergen, Bergen, Norway; and 5 The Danish MS Treatment Register, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis Journal, 7(9): , Emil Greve Pedersen, Jesper Hallas 2, Klaus Hansen 3, Poul Erik Hyldgaard Jensen 4, David Gaist 5. Department of Neurology, Odense University Hospital, Denmark, 2 Institute of Public Helath, Clinical Pharmacology Unit, University of Southern Denmark, Denmark, 3 Department of Neurology, National University Hospital, Copenhagen, Denmark, 4 Neuroimmunology unit, section 63, Department of Neurology, National University Hospital, Copenhagen, Denmark, 5 Institute of Clincal Research, Neurology Unit, University of Southern Denmark, Denmark. Identifying patients with myasthenia for epidemiological research through linkage of automated registers. Neuroepidemiology 37: 20-28, Poul Erik Hyldgaard Jensen, Nils Kock-Henriksen 2, Finn Sellebjerg, Per Soelberg Sørensen. University Hospital, Rigshospitalet, Copenhagen, Denmark, and 2 University Hospital in Aalborg, Aalborg. Prediction of antibody persistency from antibody titres to natalizumab. Multiple Sclerosis Journal 8(0): , Poul Erik Hyldgaard Jensen, Finn Sellebjerg, Helle Bach Søndergaard, Per Soelberg Sørensen. University Hospital, Rigshospitalet, Copenhagen, Denmark. Correlation between anti-interferon- binding and neutralizing antibodies ininterferon- treated multiple sclerosis patients. European Journal of Neurology 9(0)3-7, Emil Greve Pedersen, Jesper Hallas 2, Klaus Hansen 3, Poul Erik Hyldgaard Jensen 4, and David Gaist. Department of Neurology, Odense University Hospital & Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark (SDU), Odense Denmark.

8 8 2 Institute of Public Health, Clinical Pharmacology Unit, SDU, Denmark. 3 Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Denmark. 4 Neuroimmunology Laboratory, DMSC, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Denmark. Late-onset myastenia gravis not on the increase: A nationwide register study in Denmark. Eur J Neurol 20(2): 309-4, Romme Christensen, J, Börnsen, L, Khademi M 2, Olsson, T 2, Jensen PE, Sørensen, PS, Sellebjerg, F. University Hospital, Rigshospitalet, Denmark, 2 Karolinska Institutet, Department of Clinical Neurosciences, The Neuroimmunology Research group, Stockholm, Sweden. CSF markers of inflammation and axonal damage are associated in progressive multiple sclerosis. Multiple Sclerosis 9(7): , Pedersen EG, Pottegård A 2, Hallas J 3, Friis S 4, Hansen K 5, Jensen PEH 6, Gaist, D. Department of Neurology, Odense University Hospital & Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark (SDU), Odense Denmark. 2 Institute of Public Health, Clinical Pharmacology Unit, SDU, Denmark. 3 Danish Cancer Society Research Centre & Department of Public Health, University of Copenhagen, Copenhagen, Denmark, 4 Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Denmark. 5 Neuroimmunology Laboratory, DMSC, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Denmark. Use of azathioprine for non-thymoma myasthenia and risk oc cancer: A nationwide casecontrol study in Denmark. European Journal of Neurology, 20(6): 942-8, Olsson, T, Achiron, A 2, Alfredsson, L 3, Berger, T 4, Brassat, D 5, Chan, A 6, Comi, G 7, Eraksoy, M 8, Hegen, H 4, Hillert, J, Jensen, PEH 9, Moiola, L 7, Myhr, K-M 0, Oturai, A 9, Schippling, S, Siva, A 8, Sorensen, PS 9, Weber, T 2, Potts, J 3, Plavina, T 3, Paes, D 3, Subramanyam, M 3. Center for Molecular Medicine, Karolinska Hospital, Stockholm, Sweden; 2 Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel; 3 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; 4 Clinical Department of Neurology, Innsbruck Medical University, Innsbruck, Tyrol, Austria; 5 Centre de Physiopathologie Toulouse, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France; 6 Department of Experimental and Clinical Neuroimmunology, Institute for MS Research, University of Göttingen and Gemeinnützige Hertie Stiftung, Göttingen, Germany; 7 Department of Neurology and Institute of Experimental Neurology (INSPE), Vita-Salute San Raffaele University, Milan, Italy; 8 Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 9 Department of Neurology, University Hospital Rigshospitalet, Copenhagen, Denmark; 0 Haukeland University Hospital, Department of Neurology, Bergen, Norway; Institute for Neuroimmunology and Clinical MS- Research (inims), Neurologische Klinik und Poliklinik University-Hospital Hamburg- Eppendorf, Hamburg, Germany; 2 Neurologische Klinik, Marienkrankenhaus Hamburg, Academic Teaching Hospital, University of Hamburg, Hamburg, Germany; 3 Biogen Idec Inc., Weston, MA, USA.

9 9 Anti-JCV antibody prevalence in multinational multiple sclerosis cohorts. Multiple Sclerosis, 9(): 533-8, Inger-Lise Mero,2, Marte W. Gustavsen,,9 Hanne S. Sæther,2, Siri T. Flåm 2, Helle Bach Søndergaard 4, Poul Erik H. Jensen 4, Tone Berge,5, Anja Bjølgerud,9, Aslaug Muggerud,9, Jan Aarseth 6, Kjell-Morten Myhr 6,7, Elisabeth G. Celius, Finn Sellebjerg 4, Jan Hillert 3, Annette Bang Oturai 4, Ingrid Kockum 8, Benedicte A. Lie 2, Bettina Kulle Andreassen, Hanne F. Harbo,9. Department of Neurology, Oslo University Hospital, Ullevål, N-0407 Oslo, Norway, 2 Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway, 3 Karolinska Institutet, Department of Clinical Neuroscience, The Multiple Sclerosis Research Group, Center for Molecular Medicine, L8:00, Stockholm, Sweden, 4 University Hospital, Rigshospitalet, Denmark, 5 Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway, 6 The Norwegian multiple sclerosis registry and biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway, 7 KG Jebsen Centre for MS-research, Department of Clinical Medicine, University of Bergen, Bergen, Norway, 8 Karolinska Institutet, Department of Clinical Neurosciences, The Neuroimmunology Research group, Stockholm, Sweden, 9 Institute of Clinical Medicine, University of Oslo, Oslo, Norway Genetic differences relating to oligoclonal band status in multiple sclerosis. PLoS-One 8(3): Pedersen EG, Pottegård A 2, Hallas J 3, Friis S 4, Hansen K 5, Jensen PEH 6, Gaist, D. Department of Neurology, Odense University Hospital & Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark (SDU), Odense Denmark. 2 Institute of Public Health, Clinical Pharmacology Unit, SDU, Denmark. 3 Danish Cancer Society Research Centre & Department of Public Health, University of Copenhagen, Copenhagen, Denmark, 4 Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Denmark. 5 Neuroimmunology Laboratory, DMSC, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Denmark. Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. European Journal Neurology 2(3): 454-8, 204. Review articles. V. P. Shanbhag and P. E. H. Jensen*, Dept. of Biochemistry, *Dept. of Immunology, Umeå University, Umeå, Sweden Affinity Partitioning Using Poly(ethylene glycol) with Covalently Coupled Hydrophobic Groups Aqueous Two-Phase Systems: Methods and Protocols in Methods in Biotechnology, 2000, Volume, Chapter 29 (R. Hatti-Kaul, ed.), Humana Press Inc. Totowa, NJ, U.S.A.